CHMP Recommends Fruquintinib for Previously Treated Metastatic Colorectal Cancer
Takeda has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the approval of fruquintinib, a selective inhibitor of vascular endothelial…
New Supervisory Board Elected at Merck’s Annual General Meeting
Merck, a prominent science and technology company, convened its 29th Annual General Meeting virtually today. With a significant majority, shareholders approved all items on the agenda, including the proposed dividend…
European Commission Grants Approval for KALYDECO® to Treat Cystic Fibrosis in Infants as Young as 1 Month Old, Announces Vertex
Vertex Pharmaceuticals (Nasdaq: VRTX) has received approval from the European Commission for the expansion of KALYDECO® (ivacaftor) labeling. This approval allows for the treatment of infants as young as 1…
FDA Grants Approval to Pfizer’s BEQVEZ™: A Single-Dose Gene Therapy for Hemophilia B in Adults
Today, Pfizer Inc. (NYSE: PFE) announced the approval of BEQVEZ™ (fidanacogene elaparvovec-dzkt) by the U.S. Food and Drug Administration (FDA) for the treatment of adults grappling with moderate to severe…
Amgen Prepares to Present Marketing Authorization Application for Teprotumumab to the European Medicines Agency
Amgen (NASDAQ:AMGN) has announced its forthcoming submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab. Teprotumumab, a fully human monoclonal antibody and targeted inhibitor…
ATS Presentation: Sanofi’s Innovations in Immune-Mediated Respiratory Therapies
The American Thoracic Society (ATS) International Conference, scheduled from May 17-22 in San Diego, will host the unveiling of twenty-five abstracts featuring both approved and investigational medicines from Sanofi. Among…
CHMP Recommends Approval of Bristol Myers Squibb’s Opdivo® for First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma
Bristol Myers Squibb (NYSE: BMY) has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Opdivo® (nivolumab)…
First-Quarter 2024 Financial Results Released by AbbVie
AbbVie (NYSE: ABBV) has released its financial results for the first quarter ending March 31, 2024. Richard A. Gonzalez, the chairman and CEO of AbbVie, expressed satisfaction with the company’s…
Neurocrine Biosciences Launches C@H?! Initiative for Congenital Adrenal Hyperplasia Support
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has unveiled the launch of WHAT THE C@H?!, an educational initiative designed to address the information gap surrounding congenital adrenal hyperplasia (CAH) and acknowledge the…
Bio-Techne Initiates Patent Infringement Lawsuit Against Molecular Instruments
Bio-Techne Corporation (NASDAQ: TECH), a renowned global life sciences company specializing in innovative tools and bioactive reagents for both research and clinical diagnostics, has officially initiated legal proceedings in the…
Moderna Teams Up with OpenAI to Propel mRNA Medicine Innovation
Moderna, Inc. (NASDAQ: MRNA) and OpenAI have announced a collaborative effort aimed at harnessing the potential of artificial intelligence (AI) to revolutionize both business and healthcare. Moderna, known for its…
CVS Health Allocates $19.2 Million Towards Affordable Housing in Arvada, Colorado
CVS Health® (NYSE: CVS) revealed today a significant investment of $19.2 million, facilitated via Boston Financial, earmarked for the construction of 85 new affordable housing units in Arvada, Colorado. This…